N/A N=8 In Vivo Arthroscopic Behavior of the Infrapatellar Plica of the Knee
Anterior Knee Pain Syndrome
Primary: Number of Participants With Successful Recording. — 2; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=120 Effects of Pregabalin on Pain After Total Knee Arthroplasty
Primary Total Knee Arthroplasty
Primary: Postoperative Pain — 4; 4.8; 4.5; 4.0 units on a scale
Phase 4 N=130 Ropivacaine Block Alone or With Perineural or Systemic Dexamethasone for Pain in Shoulder Surgery
Shoulder Injury
Primary: Duration of Sensory Blockade — 16.9; 18.2; 13.8 hours — p=0.001
Phase 2 N=20 Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies
Ovarian Cancer · Peritoneal Cancer · Fallopian Tube Cancer
Primary: Therapy Completion Rate — .75 proportion of participants
Phase 2 N=46 Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer
Breast Neoplasms
Primary: Percent Change in Mammographic Density at 1 Year on Exemestane — -2.4 percent change from baseline
Phase 4 N=175 Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO
Retinal Vein Occlusion
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 35; 28; 45; 16 Participants
Phase 2 N=38 Investigation of the Enhancement of Response to Hepatitis B Vaccine by Lenalidomide in Plasma Cell Dyscrasias
Plasma Cell Disorder
Primary: Positive for Hepatitis B Surface Antigen — 4; 3 participants
Phase 1 N=24 A Ph1 Study in Healthy Male Japanese and Caucasian After Single and Multiple Doses of D5884(Omega-3-carboxylic Acids)
Healthy
Primary: Number of Patients With Treatment-emergent Adverse Events (TEAEs), by Treatment (Safety Analysis Set) — 2; 2; 5; 2 subjects
Phase 2 N=45 A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
GIST
Primary: Clinical Benefit Rate (CBR) in Cohort A — 35.7 percentage (%) of participants
Phase 3 N=3,362 QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Rate of COPD Exacerbations — 3.59; 4.03 COPD Exacerbations/year — p=0.003
Phase 1 N=42 A Study to Investigate the Effect of Food on Pharmacokinetics of Total EPA and Total DHA of AZD0585 in Healthy Male Japanese Subjects
Healthy
Primary: The Effect of Food Timing (Fasting, Before Meal, and After Meal) on Pharmacokinetics (PK; AUC) of AZD0585 in Healthy Male Japanese. — 2.44; 2.66; 3.80; 0.299 milligram x…
N/A N=33 Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase®
Hunter Syndrome
Primary: Number of Participants Who Were Screened For The Follow-On Study With an Investigational Agent — 17 participants
Phase 4 N=138 Does Tranexamic Acid Reduce the Need for Blood Transfusions in Patients Undergoing Hip Fracture Surgery?
Hip Fracture
Primary: Number of Participants Who Received a Hospitalization Transfusion — 18; 12 participants
Phase 2 N=30 A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
Primary: Maximal Increase From Baseline in Serum Sodium Concentration Following Tolvaptan Administration. — 3.6; 5.3; 7.9 mmol/L
N/A N=13 Treatment of Egg Allergy in Children Through Oral Desensitization (EGG OIT)
Food Hypersensitivity
Primary: Double-blind, Placebo-controlled Food Challenge (DBPCFC) to Egg — 9 subjects with no symptoms on DBPCFC